Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SIRES: ELISPOT-guided Immunosuppression in Kidney Transplant
NCT01195194Phase 4Completed
- Start
- Mar 2008
- Primary completion
- Jun 2012
- Modality
- Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of nab-sirolimus in kidney transplant rejection (2 arms). Primary endpoint: Percentage of biopsy-confirmed acute rejection episodes at 12 months. Started Mar 2008; status: completed.
02
Drugs
nab-sirolimus
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT01195194.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01195194.